

Published in final edited form as:

*Mucosal Immunol.* 2015 November ; 8(6): 1226–1236. doi:10.1038/mi.2015.13.

## Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3<sup>+</sup> Treg cell function in the intestine

OJ Harrison<sup>1</sup>, N Srinivasan<sup>1</sup>, J Pott<sup>1</sup>, C Schiering<sup>2</sup>, T Krausgruber<sup>2</sup>, NE Ilott<sup>2</sup>, and KJ Maloy<sup>1</sup>

<sup>1</sup>Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK

<sup>2</sup>Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, OX9 3DU, UK

### Abstract

Elevated levels of interleukin-18 (IL-18) are found in many chronic inflammatory disorders, including inflammatory bowel disease (IBD), and polymorphisms in the *IL18R1-IL18RAP* locus are associated with IBD susceptibility. IL-18 is an IL-1 family cytokine that has been proposed to promote barrier function in the intestine, but the effects of IL-18 on intestinal CD4<sup>+</sup> T cells are poorly understood. Here, we demonstrate that IL-18R1 expression is enhanced on both effector and regulatory CD4<sup>+</sup> T cells in the intestinal lamina propria, with Th17 cells exhibiting particularly high levels. We further show that, during steady state, intestinal epithelial cells (IEC) constitutively secrete IL-18 that acts directly on IL-18R1-expressing CD4<sup>+</sup> T cells to limit colonic Th17 cell differentiation, in part by antagonizing IL-1R1-signalling. In addition, although IL-18R1 is not required for colonic Foxp3<sup>+</sup> Treg cell differentiation, we found that IL-18R1 signaling was critical for Foxp3<sup>+</sup> Treg cell mediated control of intestinal inflammation, where it promoted expression of key Treg effector molecules. Thus, IL-18 is a key epithelial-derived cytokine that differentially regulates distinct subsets of intestinal CD4<sup>+</sup> T cells during both homeostatic and inflammatory conditions, a finding with potential implications for treatment of chronic inflammatory disorders.

### Introduction

Intestinal immune homeostasis is maintained through a constant molecular dialogue between commensal microbiota, intestinal tissue cells and the mucosal immune system <sup>1</sup>. Breakdown of this mutualistic relationship results in chronic pathologies of the gastrointestinal tract, including inflammatory bowel diseases (IBD) <sup>2</sup>. Th17 cells, dependent on the transcription factor retinoic acid-related orphan receptor- $\gamma$ t (Ror $\gamma$ t), represent a distinct interleukin (IL)-17A-producing CD4<sup>+</sup> T cell subset that contribute both to host defense from pathogens and to tissue pathologies in a number of inflammatory diseases and experimental models,

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

**Corresponding author:** Dr. Kevin J. Maloy, [kevin.maloy@path.ox.ac.uk](mailto:kevin.maloy@path.ox.ac.uk), tel: +44(0)1865 275589.

#### Disclosure.

The authors declare no competing financial interests.

including colitis<sup>3</sup>. Conversely, Foxp3<sup>+</sup> regulatory T (Treg) cells prevent systemic and tissue-specific autoimmunity, and are crucial for intestinal immune homeostasis<sup>4</sup>. In addition to induction under inflammatory conditions, Th17 cells are present within the gastrointestinal tract under homeostatic conditions. Intestinal Th17 cell differentiation occurs upon colonization by commensal microbes and is dependent upon IL-1R1-signaling on CD4<sup>+</sup> T cells<sup>5-7</sup>. IL-1 family cytokines are key co-regulators of CD4<sup>+</sup> T cell fate, and the role of IL-1 $\beta$  in Th17 cell differentiation is mirrored by the contribution of IL-33 and IL-18 to Th2 and Th1 cell subsets, respectively<sup>8</sup>. Whilst IL-18 is not essential for Th1 cell differentiation, under inflammatory conditions, IL-12 signaling promotes IL-18R1 expression on differentiating Th1 cells, whereupon IL-18 stimulation acts to enhance IFN- $\gamma$  production<sup>9-11</sup>.

Genome-wide association studies (GWAS) have revealed a number of polymorphisms associated with disease susceptibility, including association of mutations within the *IL18R1-IL18RAP* locus with both adult and severe early-onset IBD<sup>12-14</sup>. Furthermore, intestinal biopsies from IBD patients produced increased concentrations of IL-18, and exacerbated Th1 cell responses are found in patients with IBD<sup>15,16</sup>. Murine models of CD4<sup>+</sup> T cell mediated colitis have also attributed a pathogenic role to IL-18 in the intestine<sup>17</sup>.

Conversely, recent studies in mice lacking key inflammasome components that regulate the processing and secretion of IL-18, have proposed a tissue-protective role for IL-18 following injury to the intestinal epithelium<sup>18,19</sup>. Therefore, the role of IL-18 in intestinal immune regulation, as well as the key cellular sources of this cytokine in the gut, remain unclear<sup>20</sup>. Here, we demonstrate that intestinal epithelial cells (IEC) regulate colonic CD4<sup>+</sup> T cell homeostasis through production of IL-18. Under homeostatic conditions, IL-18R1-signaling limited colonic Th17 cell differentiation whereas during inflammation, Foxp3<sup>+</sup> Treg cell expression of IL-18R1 was critical for prevention of experimental colitis.

## Results

### IL-18R1<sup>+</sup> CD4<sup>+</sup> T cells are enriched in the colonic lamina propria

A diverse range of effector and regulatory CD4<sup>+</sup> T cells populates the colonic lamina propria, however, the role of IL-18R-signaling on distinct CD4<sup>+</sup> T cell subsets within the intestine remains unknown. To determine whether IL-18/IL-18R interactions might influence colonic CD4<sup>+</sup> T cells, we first investigated the expression of IL-18R components, IL-18R1 and IL-18RaP, on CD4<sup>+</sup> T cell subsets polarized *in vitro*. We detected high *Il18r1* and *Il18rap* expression on Th1, Th17 and iTreg cells compared to naïve CD4<sup>+</sup> T cells, or those cultured under Th0 or Th2-polarizing conditions (Figure 1a). Efficient polarization was confirmed by expression of subset-restricted genes (Supplementary Figure 1). To confirm these observations *in vivo*, we performed flow cytometric analysis of IL-18R1 expression by CD4<sup>+</sup> T cells present under homeostatic conditions within the colonic lamina propria. In accordance with our *in vitro* observations, IL-18R1 expression by naïve (CD62L<sup>+</sup> CD44<sup>-</sup>) CD4<sup>+</sup> T cells was low relative to effector/memory (CD44<sup>+</sup> CD62L<sup>-</sup>) CD4<sup>+</sup> T cells, both in the spleen and colon (Figure 1b). Furthermore, although IL-18R1 expression was evident on colonic Th1, Th17 and Foxp3<sup>+</sup> Treg cells (Figure 1c), the proportions of IL-18R1<sup>+</sup> cells varied among colonic CD4<sup>+</sup> T cell subsets, with IL-18R1 expressed almost

ubiquitously by Th17 cells ( $91.7 \pm 2.4\%$ ), on the majority of Th1 cells ( $70.5 \pm 2.6\%$ ), and on a significant proportion of Foxp3<sup>+</sup> Treg cells ( $40.7 \pm 2.7\%$ ; Figure 1d). Moreover, while IL-18R1 expression was also detectable on CD4<sup>+</sup> T cell subsets from the spleen and MLN, the frequency of IL-18R1<sup>+</sup> CD4<sup>+</sup> T cells was significantly lower on all CD4<sup>+</sup> T cell subsets isolated from peripheral lymphoid tissues when compared to their colonic counterparts (Figure 1d). These data demonstrate that IL-18R1<sup>+</sup> CD4<sup>+</sup> T cells are enriched within the colonic lamina propria, particularly amongst Th17 cells, and raised the possibility that IL-18 may have an important regulatory role on colonic CD4<sup>+</sup> cell populations.

### Canonical IL-18R1-signaling limits colonic Th17 cell differentiation

To determine the impact of IL-18 on colonic CD4<sup>+</sup> T cells, we assessed the frequency of colonic CD4<sup>+</sup> T cell subsets in both *Il18*<sup>-/-</sup> and *Il18r1*<sup>-/-</sup> mice. The frequency and total number of colonic CD4<sup>+</sup> T cells was unaffected in *Il18*<sup>-/-</sup> or *Il18r1*<sup>-/-</sup> mice (Supplementary Figure 2a). However, in the absence of IL-18R1-signalling the frequency of colonic effector/memory (CD62L<sup>-</sup>CD44<sup>+</sup>) CD4<sup>+</sup> T cells was significantly increased and the frequency of naïve (CD62L<sup>+</sup>CD44<sup>-</sup>) CD4<sup>+</sup> T cells was significantly decreased (Supplementary Figure 2b). Furthermore, absence of *Il18* or *Il18r1* resulted in significantly higher frequencies of colonic IL-17A and IFN- $\gamma$ -producing CD4<sup>+</sup> T cells compared to WT mice (Figure 2a,b). Expression of transcription factors Ror $\gamma$ t by IL-17A<sup>+</sup> and T-bet by IFN- $\gamma$ <sup>+</sup> cells confirmed these populations as Th17 and Th1 cells, respectively (Supplementary Figure 2c). By contrast, frequencies of Th17 and Th1 cells in the spleen and MLN were unaffected by *Il18*/*Il18r1*-deficiency (unpublished data). Elevated frequencies of colonic effector CD4<sup>+</sup> T cells were not the result of a diminished Foxp3<sup>+</sup> Treg cell population, as Foxp3<sup>+</sup> Treg cell frequencies were equivalent between *Il18*<sup>-/-</sup>, *Il18r1*<sup>-/-</sup> and WT mice (Figure 2c). Although IL-18-independent IL-18R1-signalling has been reported<sup>21</sup>, the comparable increases of colonic Th17 and Th1 cell frequencies in *Il18*<sup>-/-</sup> and *Il18r1*<sup>-/-</sup> mice indicated that colonic effector CD4<sup>+</sup> T cells are regulated by canonical IL-18/IL-18R1-signaling. In accordance with elevated frequencies of colonic Th17 cells, colonic lamina propria leukocytes isolated from *Il18r1*<sup>-/-</sup> mice and stimulated with  $\alpha$ -CD3 produced significantly more IL-17A, but not GM-CSF or IL-22, when compared to WT controls (Figure 2d). By contrast, colonic lamina propria leukocytes isolated from *Il18r1*<sup>-/-</sup> mice did not produce significantly higher levels of IFN- $\gamma$  *ex vivo* (Figure 2d), likely reflecting additional sources of IFN- $\gamma$  besides Th1 cells. In addition, expression of genes encoding the antimicrobial peptides S100A8 and S100A9 induced by IL-17A, but not IL-22-induced Reg3 $\gamma$ , were significantly elevated in colonic tissue of *Il18r1*<sup>-/-</sup> mice when compared to WT controls (Figure 2e). The increased frequency of colonic Th17 cells observed in *Il18*<sup>-/-</sup> and *Il18r1*<sup>-/-</sup> mice was not due to elevated colonization by segmented filamentous bacteria (SFB) as *Il18*<sup>-/-</sup>, *Il18r1*<sup>-/-</sup> and WT mice had comparable SFB colonization (Supplementary Figure 2d). Moreover, all 3 genotypes were co-housed for at least 3 weeks prior to analysis, in order to circumvent any potential effects of the commensal microbiota. Overall, these data show that canonical IL-18/IL-18R1-signaling limits colonic Th17 cell differentiation under homeostatic conditions.

## Intestinal epithelial cell production of IL-18 limits colonic Th17 cell differentiation

We next sought to determine the cellular source of IL-18 within the steady state intestine. Amongst the heterogeneous populations of intestinal myeloid cells, tissue resident macrophages produce IL-1 $\beta$  upon microbial colonization to drive intestinal Th17 cell differentiation<sup>7</sup>, and both IL-1 $\beta$  and IL-18 are dependent upon caspase-1 processing for their maturation<sup>22</sup>. However, during DSS-induced acute colitis, non-hematopoietic cell expression of caspase-1 appeared to mediate tissue protective responses that were associated with IL-18<sup>18,19</sup>. Furthermore, transcriptional analyses demonstrated that *Il18* gene expression by intestinal epithelial cells (IEC) was elevated in the presence of commensal microbes<sup>23</sup>. Thus, we hypothesized that IEC might represent the major source of IL-18 within the homeostatic intestine. Accordingly, immunofluorescence analysis of colonic tissue identified extensive cytoplasmic IL-18 staining within E-cadherin<sup>+</sup> IEC, whereas there were extremely few IL-18<sup>+</sup> cells within the underlying lamina propria (Figure 3a). Complementary studies utilizing Western blot analysis of enriched colonic IEC and LPL cell fractions confirmed this observation, with expression of mature IL-18 almost exclusively restricted to the IEC fraction (Figure 3b). Thus, IEC represent the major source of IL-18 within the intestine under homeostatic conditions.

To examine the role of IEC-derived IL-18 on colonic CD4<sup>+</sup> T cells, we generated bone marrow (BM) chimeric mice by reconstituting lethally irradiated WT or *Il18*<sup>-/-</sup> mice with either WT or *Il18*<sup>-/-</sup> bone marrow cells. Consistent with our findings in *Il18*<sup>-/-</sup> mice, we observed that *Il18*<sup>-/-</sup>→*Il18*<sup>-/-</sup> control chimeras had significantly increased frequencies of colonic Th17 cells compared to WT→WT controls (Figure 3c,d). Furthermore, selective ablation of *Il18* in hematopoietic cells (*Il18*<sup>-/-</sup>→WT chimeras) did not alter colonic Th17 cell frequency compared to WT→WT controls, whereas selective ablation of *Il18* in non-hematopoietic cells (WT→*Il18*<sup>-/-</sup> chimeras) resulted in significantly increased frequencies of colonic Th17 cells (Figure 3c,d). Conversely, in this chimeric setting, IEC-derived IL-18 slightly enhanced colonic Th1 cell differentiation, as WT→*Il18*<sup>-/-</sup> and *Il18*<sup>-/-</sup>→*Il18*<sup>-/-</sup> mice had slight reductions in colonic Th1 cell frequencies when compared to WT→WT control mice (Figure 3c,d). Expression of Ror $\gamma$ t by IL-17A<sup>+</sup> and T-bet by IFN- $\gamma$ <sup>+</sup> cells confirmed these populations as Th17 and Th1 cells, respectively (Supplementary Figure 3). In contrast to effector CD4<sup>+</sup> T subsets, Foxp3<sup>+</sup> Treg cell frequencies were unaffected by the absence of IEC-derived IL-18 (Figure 3d). Thus, under steady state conditions, IEC are the primary source of constitutive IL-18 production in the gut, which acts to limit colonic Th17 cell differentiation.

## Cell-intrinsic IL-18R1-signaling regulates colonic Th17 cell differentiation

To establish whether cell-intrinsic IL-18R1-signaling limited colonic Th17 cell differentiation, lethally irradiated *Rag1*<sup>-/-</sup> mice were adoptively transferred with a 1:1 mixture of bone marrow cells from WT (CD45.1) and *Il18r1*<sup>-/-</sup> (CD45.2) donors. Equivalent reconstitution of WT and *Il18r1*<sup>-/-</sup> B220<sup>+</sup> B cells, CD8<sup>+</sup> and CD4<sup>+</sup> T cells within the spleen, MLN and colonic lamina propria indicated that *Il18r1*-deficiency did not generally effect lymphocyte reconstitution (Supplementary Figure 4a). However, further analyses revealed significantly higher frequencies of colonic Th17 cells were derived from *Il18r1*<sup>-/-</sup> CD4<sup>+</sup> T cells when compared to WT CD4<sup>+</sup> T cells (Figure 4a-c). Furthermore, IL-18R1-signaling

limited Th17 cell differentiation solely within the colonic lamina propria, as *Il18r1*<sup>-/-</sup> CD4<sup>+</sup> T cells and WT CD4<sup>+</sup> T cells gave rise to comparable Th17 cell frequencies in the MLN and spleen (Figure 4c). In contrast, IL-18R1-signaling played a global role in promoting Th1 cell differentiation following lymphopenic expansion in this competitive chimeric environment, as significantly lower frequencies of Th1 cells were derived from *Il18r1*<sup>-/-</sup> CD4<sup>+</sup> T cells in colonic lamina propria, MLN and spleen (Figure 4c). However, frequencies of Foxp3<sup>+</sup> Treg cells were again unaffected by *Il18r1*-deficiency throughout these chimeric mice (Figure 4c).

To investigate the mechanism by which IL-18 limits Th17 cell differentiation we performed parallel *in vitro* studies. We utilized a Th17 cell differentiation system whereby co-culture of naïve (CD62L<sup>+</sup> CD44<sup>-</sup> CD25<sup>-</sup>) CD4<sup>+</sup> T cells with BM-derived dendritic cells (BMDC) in the presence of α-CD3, LPS and TGFβ<sub>1</sub> results in efficient Th17 cell polarization<sup>24</sup>. Under these polarizing conditions, addition of IL-18 significantly inhibited Th17 cell differentiation from WT naïve CD4<sup>+</sup> T cells, whereas *Il18r1*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells differentiated more efficiently into Th17 cells than WT naïve CD4<sup>+</sup> T cells, and this was not inhibited by addition of IL-18, confirming that IL-18 acts directly on CD4<sup>+</sup> T cells to limit Th17 cell differentiation (Figure 4d,e). Expression of Rorγt by IL-17A-producing cells confirmed these as Th17 cells (Supplementary Figure 4b), whereas T-bet and Foxp3 expression remained undetectable (unpublished data). Inhibition of Th17 cell differentiation by IL-18 appeared to occur independently of effects on cellular proliferation, or apoptosis (Supplementary Figure 4c,d). Together, these data confirm that IL-18 acts directly on CD4<sup>+</sup> T cells to limit Th17 cell differentiation.

Both IL-1β and IL-18 signal through TIR-domain containing receptors that are dependent upon the MyD88 signaling adaptor, in a manner akin to that of Toll-like receptors<sup>25,26</sup>. We therefore sought to address the seemingly opposing roles of IL-1β and IL-18 on Th17 cell differentiation. In line with previous reports<sup>27</sup>, *Il1r1*<sup>-/-</sup> or *Myd88*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells co-cultured with BMDC under Th17 cell polarizing conditions yielded significantly decreased frequencies of Th17 cells when compared to WT naïve CD4<sup>+</sup> T cells (Figure 4f,g). Strikingly, both IL-1R1 and MyD88 expression were required for IL-18-mediated inhibition of Th17 cell differentiation, as IL-18 significantly inhibited Th17 cell differentiation from WT CD4<sup>+</sup> T cells, but not from *Il1r1*<sup>-/-</sup> or *Myd88*<sup>-/-</sup> CD4<sup>+</sup> T cells (Figure 4f,g). Thus, IL-18 may limit Th17 cell differentiation by antagonizing MyD88-dependent signaling effectors downstream of IL-1R1. Together, these data demonstrate that IEC production of IL-18 acts via IL-18R1 directly on CD4<sup>+</sup> T cells to regulate colonic Th17 cell differentiation.

### CD4<sup>+</sup> T cell intrinsic IL-18R1 signaling is dispensable for induction of colitis

To assess the role of IL-18R1-signaling in induction of CD4<sup>+</sup> T cell mediated intestinal inflammation, we utilized the T cell transfer colitis model, whereby severe colitis and wasting disease are induced by reconstitution of lymphopenic hosts with naïve CD4<sup>+</sup> T cells<sup>28</sup>. Initially we sought to determine the cellular source of IL-18 during intestinal inflammation, as whilst IEC are a major source of IL-18 during homeostasis (Figure 3a), the key cellular source of IL-18 during chronic colitis remains unclear<sup>20</sup>. Immunofluorescence analysis of colonic tissue from *Rag1*<sup>-/-</sup> mice adoptively transferred with WT naïve CD4<sup>+</sup> T

cells demonstrated that IEC remain the major source of IL-18 within the inflamed colon, with IL-18 staining largely restricted to E-cadherin<sup>+</sup> cells of the intestinal epithelium (Figure 5a). However, despite continued production of IL-18 by IEC during chronic colitis, we found equivalent levels of wasting disease and severe colitis in *Rag1*<sup>-/-</sup> recipients of WT or *Il18r1*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells (Figure 5b,c). To assess the role of IL-18R1-signalling on colonic CD4<sup>+</sup> T cell differentiation *in vivo* under inflammatory conditions, we isolated colonic lamina propria leukocytes from *Rag1*<sup>-/-</sup> recipients that received WT or *Il18r1*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells and identified Th1, Th17 and Foxp3<sup>+</sup> T cell populations by flow cytometry. We observed similar frequencies of IL-17A<sup>+</sup> Th17 and IL-17A<sup>+</sup> IFN- $\gamma$ <sup>+</sup> double-producing CD4<sup>+</sup> T cells in the inflamed colons of *Rag1*<sup>-/-</sup> mice that received WT or *Il18r1*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells (Supplementary Figure 5a,b). Furthermore, although the frequencies of IFN- $\gamma$ <sup>+</sup> Th1 cells were slightly decreased in the colons of *Rag1*<sup>-/-</sup> mice receiving *Il18r1*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells when compared to those receiving WT naïve CD4<sup>+</sup> T cells, this was not statistically significant (Supplementary Figure 5a,b). Finally, the differentiation of small numbers of Foxp3<sup>+</sup> iTreg cells that occurs in this model<sup>29</sup> was not dependent upon IL-18R1-signalling, as *Rag1*<sup>-/-</sup> recipient mice receiving WT or *Il18r1*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells had equivalent frequencies of colonic Foxp3<sup>+</sup> iTreg cells (Supplementary Figure 5c). Together, these data indicate that CD4<sup>+</sup> T cell intrinsic IL-18R1 signaling is dispensable for induction of intestinal inflammation upon adoptive transfer of naïve CD4<sup>+</sup> T cells into a lymphopenic environment.

### Canonical IL-18R1-signaling is critical for Foxp3<sup>+</sup> Treg cell mediated control of colitis

Although colonic Foxp3<sup>+</sup> Treg cells expressed IL-18R1 during homeostasis (Figure 1d), IL-18R1-deficiency did not alter the frequency of this cellular population (Figure 2c). However, we hypothesized that IL-18R1-signaling on Foxp3<sup>+</sup> Treg cells may influence their function within the colonic lamina propria. To address this question, we utilized a modification of the T cell transfer colitis model, whereby co-transfer of Foxp3<sup>+</sup> Treg cells prevents naïve CD4<sup>+</sup> T cell-mediated wasting disease and intestinal inflammation<sup>30</sup>. To ensure Foxp3<sup>+</sup> Treg cell purity, and facilitate detection of IL-10 production by Foxp3<sup>+</sup> Treg cells, we crossed *Il18r1*<sup>-/-</sup> mice with Foxp3<sup>hCD2</sup> mice<sup>31</sup> and IL-10<sup>gfp</sup> mice<sup>32</sup> to generate WT and *Il18r1*<sup>-/-</sup> Foxp3<sup>hCD2</sup> IL-10<sup>gfp</sup> mice, from which Foxp3<sup>+</sup> Treg cells were isolated based on hCD2 expression. First, we analyzed IL-18R1 expression by Foxp3<sup>+</sup> Treg cells during control of colitis in *Rag1*<sup>-/-</sup> mice that received both WT naïve CD4<sup>+</sup> T cell and WT Foxp3<sup>+</sup> CD4<sup>+</sup> T cells. Four weeks post transfer, 86.0 ± 8.1% of colonic Foxp3<sup>+</sup> Treg cells were IL-18R1<sup>+</sup> (Figure 6a,b), suggesting a functional role for IL-18R1-signalling in control of colitis. To directly address this, *Rag1*<sup>-/-</sup> mice received WT naïve CD4<sup>+</sup> T cells alone, or in combination with WT or *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells (CD45.2). As expected, co-transfer of WT Foxp3<sup>+</sup> Treg cells completely prevented wasting disease and colitis induced by naïve CD4<sup>+</sup> T cells (Figure 6c-e). By contrast, *Rag1*<sup>-/-</sup> mice receiving naïve CD4<sup>+</sup> T cells and *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells developed wasting disease and severe intestinal inflammation (Figure 6c-e). *Rag1*<sup>-/-</sup> mice receiving *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells alone did not develop colitis, indicating that *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells do not acquire pathogenic potential upon transfer to lymphopenic hosts (Figure 6c-e). Importantly, we observed equivalent levels of reconstitution and maintenance of Foxp3 expression by both WT and *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells (Figure 6f). Furthermore, Foxp3<sup>+</sup> IL-10<sup>+</sup> Treg cell frequencies were elevated in the

absence of IL-18R1-signaling (Figure 6f), likely in response to the on-going intestinal inflammation (Figure 6d,e). Thus, the inability of *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells to suppress colitis was not due to inefficient reconstitution, loss of Foxp3 expression or failure to produce IL-10.

### Canonical IL-18R1-signaling promotes Foxp3<sup>+</sup> Treg cell effector molecule expression

We next characterized the effects of IL-18R1-signaling on colonic Foxp3<sup>+</sup> Treg cells by comparing gene expression profiles of WT and *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells during prevention of colitis. Thus, *Rag1*<sup>-/-</sup> mice received WT naïve CD4<sup>+</sup> T cells and WT CD4<sup>+</sup> CD25<sup>+</sup> Treg cells (both CD45.1) together with either WT or *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells (CD45.2). Four weeks post transfer, colonic CD45.2<sup>+</sup> WT or *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells were isolated and comparative whole transcriptome analysis performed. Amongst transcripts differentially expressed by *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells, we identified 1606 and 2153 probes to be significantly elevated, or decreased, respectively, compared to WT controls (Supplementary Figure 6a). Although differentially expressed transcripts showed consistent clustering across the *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cell samples, we did not identify any significantly enriched pathways using Gene Ontology (GO) or KEGG analysis. Nonetheless, amongst transcripts positively regulated by IL-18R1-signaling, we identified numerous genes associated with the Foxp3<sup>+</sup> Treg cell signature and effector functions (Supplementary Figure 6a). Subsequent qRT-PCR analysis verified significantly lower expression of the majority of these genes by *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells (Figure 6g). Furthermore, these validated transcripts included multiple protein-coding genes previously demonstrated as being critical for suppression of T cell-mediated colitis by Treg cells, including *Furin*, *Bcl11b*, *Tnfrsf4* and *Stat3*<sup>33-36</sup>. Finally, canonical IL-18-dependent IL-18R1-signalling promoted gene expression changes in Foxp3<sup>+</sup> Treg cells, as acute stimulation of Foxp3<sup>+</sup> Treg cells with IL-18 resulted in elevated expression of a number of these transcripts (Supplementary Figure 6b). Taken together, these results indicate that although IL-18R1 signals are not required for Foxp3<sup>+</sup> Treg cell differentiation, they promote optimal Foxp3<sup>+</sup> Treg cell function within the colonic lamina propria by enhancing expression of key Foxp3<sup>+</sup> Treg cell effectors.

## Discussion

Accumulating evidence demonstrates key roles for IL-1 family cytokines in promoting effector and regulatory CD4<sup>+</sup> T cell responses at mucosal barrier surfaces. IL-1 $\beta$  promotes Th17 cell differentiation under homeostatic and inflammatory conditions, whilst IL-33 enhances colonic Foxp3<sup>+</sup> Treg cell function to limit intestinal inflammation<sup>7,37,38</sup>. We now identify complementary roles for IL-18 in limitation of homeostatic Th17 cell differentiation and in promotion of Foxp3<sup>+</sup> Treg cell function to limit tissue pathology during experimental colitis. In addition, our findings place canonical IL-18/IL-18R1-signaling at the center of a key epithelial/T-cell immune-regulatory axis in the intestine.

Basal activation of innate immune pathways at mucosal surfaces, particularly within the gastrointestinal tract, is key for maintenance of tissue homeostasis. The commensal dysbiosis and elevated susceptibility to acute experimental DSS colitis observed in mice

lacking Nod-like receptor (NLR) components, demonstrates the crucial role of inflammasome activation in maintenance of intestinal homeostasis<sup>18,19,39</sup>. The protective effects of inflammasome activation in the intestine have been partly attributed to the production of IL-18, which may be important in restoring and maintaining epithelial barrier integrity<sup>18,19</sup>. Conversely, evidence for a pathogenic role for IL-18 in experimental CD4<sup>+</sup> T cell mediated colitis<sup>17</sup>, together with elevated tissue levels of IL-18 reported in patients with IBD<sup>15,16</sup>, suggest this cytokine may contribute to chronic intestinal inflammation. However, little is known of the direct cellular targets of IL-18 within the gastrointestinal tract, nor the downstream consequences of this interaction<sup>20</sup>. We focused our investigation to the modulation of intestinal CD4<sup>+</sup> T cell populations by IL-18, and the functional activities of this pathway during intestinal homeostasis and inflammation. We observed high IL-18R1 expression by effector/memory CD4<sup>+</sup> T cells, particularly within the colonic lamina propria, reflective of the elevated activation status of intestinal CD4<sup>+</sup> T cells<sup>40</sup>. However, we observed discordant levels of IL-18R1 expression by distinct effector and regulatory intestinal CD4<sup>+</sup> T cell subsets, with highest expression by colonic Th17 cells. Local exposure of colonic Th17 cells to IL-23 may bolster IL-18R1 expression, as *Il18r1* expression is positively regulated by IL-23 signaling in developing Th17 cells<sup>41</sup>.

Although our results indicated that colonic CD4<sup>+</sup> T cells were poised to respond to IL-18 under homeostatic conditions, the cellular source of this cytokine remained unclear. Using both immunofluorescence and Western blotting, we observed production of IL-18 from E-cadherin<sup>+</sup> intestinal epithelial cells during homeostatic conditions, consistent with previous reports that a non-hematopoietic source of IL-18 promotes tissue protective responses during acute DSS colitis<sup>18,19</sup>. Interestingly, IL-18 production appeared restricted to IEC outside of the crypt base, suggesting that IL-18 production is limited to mature epithelial cells, or that IL-18 production is triggered in response to microbial stimulation outside of the relatively sterile crypt base. The factors that regulate IL-18 production by IEC require additional investigation, but it has been reported that commensal microbes may augment *Il18* gene expression by IEC<sup>23</sup>. Homeostatic production of IL-18 by IEC and high IL-18R1 expression by colonic CD4<sup>+</sup> T cells led us to investigate the role of this axis in immune regulation in the steady state intestine. Notably, absence of canonical IL-18R1-signalling resulted in elevated frequencies of colonic Th17 cells under homeostatic conditions. Although expression of IL-18R1 by colonic Th17 cells suggested that IL-18 could act directly on this cell population to limit their differentiation, we also considered the possibility that the absence of functional IL-18R1-signaling in another leukocyte population (for example, in Foxp3<sup>+</sup> Treg cells) may have indirectly led to the increased frequency of colonic Th17 cells. However, competitive bone marrow chimera experiments demonstrated that cell-intrinsic IL-18R1-signaling acted to limit colonic Th17 cell differentiation. Thus, IEC-derived IL-18 acts directly on colonic CD4<sup>+</sup> T cells to limit Th17 cell differentiation under homeostatic conditions. Like Toll-like receptors (TLR), the IL-1 family cytokines IL-1 $\beta$  and IL-18 signal through TIR-domain containing receptors, dependent upon the signaling adaptor, MyD88<sup>25</sup>. In accordance with a cell-intrinsic role for canonical IL-18R1-signalling in limiting Th17 cell differentiation, addition of IL-18 decreased the efficiency of Th17 cell differentiation by acting directly on CD4<sup>+</sup> T cells. However, CD4<sup>+</sup> T cell expression of IL-1R1 or MyD88 was required for IL-18 to limit Th17 cell differentiation,



suggesting that IL-18 limits Th17 cell differentiation in part by antagonizing signaling downstream of IL-1R1. Future work is necessary to better understand how distinct MyD88-dependent signaling cascades can warrant opposing transcriptional responses, an area that remains poorly understood despite extensive investigation in the context of TLR signaling.

In contrast to the clear inhibitory effects of IL-18R1 signaling on intestinal Th17 differentiation, we observed opposing effects of IL-18R1 ablation on colonic Th1 cell development under homeostatic conditions and in the competitive bone marrow chimeras. Under steady state conditions IL-18R1-signaling limited Th1 differentiation, evidenced by the increased frequencies of Th1 cells found in *Il18<sup>-/-</sup>* and *Il18r1<sup>-/-</sup>* mice compared to WT mice. However, in the bone marrow chimeric mice IL-18 promoted Th1 cell differentiation, as *Il18r1<sup>-/-</sup>* CD4<sup>+</sup> T cells had reduced frequencies of Th1 cells relative to WT CD4<sup>+</sup> T cells. We hypothesize that intestinal epithelial barrier damage and lymphopenia-induced proliferation following irradiation<sup>42</sup> creates an inflammatory environment in the bone marrow chimeric mice, in which IL-18 plays a more classical role in augmenting Th1 cell responses<sup>8</sup>. Indeed, the overall frequencies of effector CD4<sup>+</sup> T cells found in the intestines of the bone marrow chimeras were markedly higher than those observed in steady state mice. However, we cannot exclude the possibility of a cell-extrinsic role for IL-18R1-signalling, perhaps through Foxp3<sup>+</sup> Treg cell function, in control of colonic Th1 cell differentiation under homeostatic conditions.

We also addressed the role of the IL-18/IL-18R1-signaling axis in the induction and regulation of CD4<sup>+</sup> T cell mediated intestinal inflammation. Our experiments suggested that IEC remained a key source of IL-18 during experimental CD4<sup>+</sup> T cell mediated intestinal inflammation, as we observed robust IL-18 staining in E-cadherin<sup>+</sup> IEC and very few IL-18<sup>+</sup> cells within the lamina propria compartment. This observation contrasts with findings from patients with Crohn's disease, where the increased levels of IL-18 present in inflamed lesions coincided with increased accumulation of IL-18<sup>+</sup> CD68<sup>+</sup> macrophages in the lamina propria<sup>16,43</sup>. These observations may reflect some of the inherent differences between the inflammatory characteristics of experimental T cell transfer colitis in mice and Crohn's disease. However, a comprehensive investigation into the cellular sources of bioactive IL-18 within the human intestine during health and disease could help explain its context-dependent protective or pathogenic activities. Whilst IEC remained a major source of IL-18 during colitis, IL-18R1-signaling on CD4<sup>+</sup> T cells was dispensable for induction of intestinal inflammation, as *Rag1<sup>-/-</sup>* recipients of *Il18r1<sup>-/-</sup>* naive CD4<sup>+</sup> T cells developed colitis of equivalent severity and with similar kinetics as those that received WT naive CD4<sup>+</sup> T cells. A previous study provided evidence of a pathogenic role for IL-18 in the effector phase of T cell transfer colitis, as administration of a recombinant adenovirus expressing IL-18 antisense mRNA to mice with established colitis led to a reduction in intestinal pathology<sup>17</sup>. Although this appears to conflict with our findings, a lack of requirement for T cell intrinsic IL-18R1 signals for disease induction does not preclude a contribution of IL-18 to the perpetuation of established inflammation. Indeed, we found that during severe inflammation in the colonic lamina propria, IL-18R1-signalling no longer limited Th17 cell differentiation, and slightly, but not significantly, enhanced Th1 cell differentiation. This indicates that the effects of IL-18 on intestinal T cell responses may vary depending on local conditions within the gut.

Finally, we found that although IL-18R1 signals were dispensable for the differentiation of intestinal Foxp3<sup>+</sup> Treg cells during steady state, expression of IL-18R1 by Foxp3<sup>+</sup> Treg cells was essential for Treg cell suppression of intestinal inflammation in the T cell transfer colitis model. Mechanistic analyses demonstrated that although IL-18R1 signaling did not affect Treg cell reconstitution, maintenance of Foxp3 expression or IL-10 production, canonical IL-18R1-signaling promoted expression of a number of key Foxp3<sup>+</sup> Treg cell effector molecules previously demonstrated to be critical for control of colitis by Treg cells, including *Furin*, *Bcl11b*, *Tnfrsf4* and *Stat3*<sup>33-36</sup>. In the context of IBD, elevated levels of IL-18 in intestinal tissues have been proposed to contribute to immunopathology by promoting effector Th1 cell responses. However, our results suggest that, during intestinal inflammation, IEC-derived IL-18 contributes to a negative feedback loop to regulate intestinal inflammation by promoting optimal function of Foxp3<sup>+</sup> Treg cells. Thus, IL-18 acts as a tissue-specific modifying factor that boosts intestinal Foxp3<sup>+</sup> Treg cell effector function. Of relevance to clinical settings, polymorphisms within the *IL18R1-IL18RAP* locus leading to decreased IL-18R component expression have been identified by genome-wide association studies to be associated with both adult and early-onset IBD<sup>12-14</sup>. In light of our results, it is tempting to speculate that attenuated canonical IL-18R1-signaling in intestinal Treg cell may provide a potential mechanistic basis for the link between common variants in the *IL18R1-IL18RAP* locus and susceptibility to both adult and early-onset IBD. In summary, our results place IL-18 at the centre of a regulatory axis through which IEC modulate local T cell responses in the gut. They further suggest that strategies targeting IL-18 in the context of IBD should be employed with caution, as they may disrupt important regulatory circuits that act to limit intestinal inflammation.

## Materials and Methods

### Mice

WT (C57BL/6), B6.*SJL-CD45.1* (CD45.1), B6 *Rag1*<sup>-/-</sup>, B6 *Il18*<sup>-/-</sup>, B6 *Il18r1*<sup>-/-</sup>, B6 Foxp3<sup>hCD2</sup> and B6 IL-10<sup>gfp</sup> mice were maintained under specified pathogen free conditions in accredited facilities at the University of Oxford, UK. B6 *Il18r1*<sup>-/-</sup>, Foxp3<sup>hCD2</sup> and IL-10<sup>gfp</sup> mice were crossed to generate B6 *Il18r1*<sup>-/-</sup> Foxp3<sup>hCD2</sup> IL-10<sup>gfp</sup> mice. All procedures on mice were conducted in accordance with the UK Scientific Procedures Act (1986) under a project license (PPL) authorized by the UK Home Office Animal Procedures Committee and approved by the Sir William Dunn School of Pathology Local Ethical Review Committee. Mice were routinely screened for *Helicobacter* species and were 6 weeks of age when first used.

### CD4<sup>+</sup> T cell purification

Bulk CD4<sup>+</sup> T cells were purified from spleen and peripheral lymph nodes by negative selection. Naive CD4<sup>+</sup> T cells for *in vivo* use were sorted as CD4<sup>+</sup> CD25<sup>-</sup> CD45RB<sup>Hi</sup>, whilst regulatory T cells were sorted as CD4<sup>+</sup> hCD2<sup>+</sup> or CD4<sup>+</sup> CD25<sup>+</sup>. Naive T cells for *in vitro* use were sorted as CD4<sup>+</sup> CD25<sup>-</sup> CD44<sup>-</sup> CD62L<sup>+</sup>. Cells were sorted on a MoFlo (Dako, Glostrup, Denmark) or AriaIII (BD Bioscience, San Jose, CA), routinely to >99% purity.

### T cell transfer model of colitis

Naive CD4<sup>+</sup> CD25<sup>-</sup> CD45RB<sup>Hi</sup> T cells from CD45.1, WT or *Il18r1*<sup>-/-</sup> mice were transferred via *i.p.* injection to sex-matched B6 *Rag1*<sup>-/-</sup> recipient mice ( $4 \times 10^5$  cells/mouse). WT or *Il18r1*<sup>-/-</sup> CD4<sup>+</sup> Foxp3<sup>+</sup> Treg cells were co-transferred in the same *i.p.* injection where indicated ( $2 \times 10^5$  cells/mouse). For transcriptome analysis,  $2 \times 10^5$  CD45.1 CD4<sup>+</sup> CD25<sup>+</sup> cells were also transferred in order to prevent intestinal inflammation in hosts receiving *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells. Mice were monitored weekly for wasting disease and mice losing >20% initial weight, or developing clinical signs of colitis were euthanized.

### Histological assessment of intestinal inflammation

Histological analysis of colitis was performed as described<sup>44</sup>. Briefly, mice were euthanized 4-7 weeks following T cell transfer and samples of proximal, mid and distal colon were fixed in 10% formalin. Paraffin-embedded samples were cut into 4 $\mu$ m-sections, H&E stained and inflammation was scored in a blinded fashion. Inflammation was graded semi-quantitatively on a scale from 0 – 3, for 4 criteria; (a) epithelial hyperplasia and goblet cell depletion, (b) lamina propria leukocyte infiltration, (c) area of tissue affected, (d) markers of severe inflammation, including crypt abscesses, sub-mucosal inflammation and ulceration. Scores for individual criteria were totaled for an overall inflammation score between 0 and 12.

### Generation of bone marrow chimeras

Bone marrow cells were isolated from CD45.1, WT, *Il18*<sup>-/-</sup> or *Il18r1*<sup>-/-</sup> mice and transferred singularly or mixed at 1:1 ratio (as indicated) into lethally irradiated (1100 Rad, split dose) recipients via *i.v.* injection (total  $1 \times 10^7$  cells/mouse). Mice were allowed to reconstitute for > 6 weeks before analysis.

### Isolation of cells and FACS analysis

Cell suspensions were prepared from spleen, MLN, colonic lamina propria and bone marrow as previously described<sup>34</sup>. Enriched IEC fractions were isolated by incubation of total colonic tissue in RPMI 1640, 5% FCS, 25mM EDTA for 15 min before collection of liberated intestinal epithelial cells. All antibodies for flow cytometry were from eBioscience, apart from  $\alpha$ -IL-18R1 (R&D Systems, Minneapolis, MN). Data was acquired using a Cyan ADP (Beckman Coulter, High Wycombe, UK) or BD Fortessa (BD Bioscience) and analyzed using FlowJo software (Tree Star Inc., Ashland, OR).

### Th17 cell polarization with BMDC

Naive CD4<sup>+</sup> T cell and dendritic cell co-culture was adopted from studies reported previously<sup>24</sup>. Briefly, FACS sorted naïve CD4<sup>+</sup> CD25<sup>-</sup> CD44<sup>-</sup> CD62L<sup>+</sup> T cells ( $2.5 \times 10^5$ ) from WT, *Il18r1*<sup>-/-</sup>, *Il1r1*<sup>-/-</sup> or *Myd88*<sup>-/-</sup> mice were activated with 1 $\mu$ g/ml soluble  $\alpha$ -CD3 (clone 145-2C11) and bone marrow-derived dendritic cells from WT mice ( $1 \times 10^5$ ) in the presence of 1ng/ml TGF $\beta$ <sub>1</sub>, 100ng/ml LPS,  $\alpha$ -IFN- $\gamma$  and  $\alpha$ -IL-4 (both 10 $\mu$ g/ml)  $\pm$  IL-18 (10ng/ml).

### Polarization and stimulation of CD4<sup>+</sup> T cell subsets

Naïve CD4<sup>+</sup> T cells cultured on  $\alpha$ -CD3/CD28 were activated with 5 $\mu$ g/ml  $\alpha$ -CD3 and 2 $\mu$ g/ml  $\alpha$ -CD28 for Th0, or in the presence of IL-12 (10ng/ml),  $\alpha$ -IL-4 (10 $\mu$ g/ml) for Th1, IL-4 (20ng/ml),  $\alpha$ -IFN- $\gamma$  (10 $\mu$ g/ml) for Th2, TGF- $\beta$ <sub>1</sub> (250pg/ml), IL-1 $\beta$  (10ng/ml), IL-6 (20ng/ml), IL-23 (10ng/ml),  $\alpha$ -IFN- $\gamma$ ,  $\alpha$ -IL-4 (both 10 $\mu$ g/ml) for Th17, and TGF- $\beta$ <sub>1</sub> (5ng/ml), IL-2 (100U/ml)  $\alpha$ -IFN- $\gamma$ ,  $\alpha$ -IL-4 (both 10 $\mu$ g/ml) for iTreg polarization. Cells were cultured in IMDM, 10% FCS, 2mM L-glutamine, 100U/ml of Penicillin/Streptomycin and 0.05mM 2-mercaptoethanol in 1ml media in a 48 well plate. Sorted Foxp3<sup>+</sup> Treg cells were activated for 24hr with 5 $\mu$ g/ml  $\alpha$ -CD3 and 2 $\mu$ g/ml  $\alpha$ -CD28 and then stimulated for 45mins with media or IL-18 (10ng/ml).

### Immunofluorescence

Colonic tissue samples were formalin-fixed, paraffin-embedded and sectioned as per histological analysis. Sections were deparaffinised, rehydrated and subjected to sodium citrate based antigen retrieval, then stained with rabbit  $\alpha$ -IL-18 (Abcam, Milton, UK), mouse  $\alpha$ -E-cadherin (BD Bioscience), goat  $\alpha$ -rabbit Alexa-555 and goat  $\alpha$ -mouse Alexa488 (Life Technologies, Paisley, UK) and counterstained with DAPI. Images were acquired with an Olympus Fluoview FV1000 confocal microscope and Olympus Fluoview Software (Olympus, Tokyo, Japan).

### Quantitation of gene expression

Total RNA from tissue samples or frozen cells was purified using RNeasy kits (Qiagen, Hilden, Germany). Tissue homogenization was performed using a FastPrep 24 Homogenizer (MP Biomedicals, Burlingame, CA). cDNA was synthesised using Superscript III reverse transcriptase and Oligo d(T) primers (Invitrogen, Carlsbad, CA). Reactions were assayed in triplicate on a Chromo4 detection system (MJ Research, Waltham, MA) with expression levels for individual samples normalized relative to *Hprt1* (Qiagen).

### Transcriptome analysis

Whole transcriptome analysis was performed with 2-3 biological replicates per experimental group, with each sample pooled from 4 mice. Total RNA using RiboPure kit (Ambion, Austin, TX), amplified using TargetAmp 2-Round Biotin-aRNA Amplification Kit (Cambio, Cambridge, UK) and whole genome expression profiled using Single-Color MouseWG-6\_V2BeadChip with direct hybridization assay (Illumina, San Diego, CA). Cy3 fluorescence emissions were imaged using iScan system (Illumina).

Signal intensities generated using GenomeStudio 2011 software (Illumina) were background corrected and subjected to variance stabilizing transformation (VST) implemented in the Lumi package from R/Bioconductor<sup>45</sup>. Quantile normalised signal intensities were used for differential expression analysis implemented in Limma<sup>46</sup>. Probes below a Benjamini-Hochberg derived adjusted p-value of 0.1 were deemed significant. Microarray data are deposited with ArrayExpress and available under accession code E-MTAB-3067.

## Western blot analysis

Total protein extracts were generated by homogenizing snap-frozen colonic tissue in RIPA buffer containing protease inhibitor cocktail (Roche, Basel, Switzerland). Protein levels were normalized by Lowry assay (Bio-Rad Laboratories, Hercules, CA), resolved by SDS-PAGE electrophoresis and analyzed with  $\alpha$ -IL-18 (Abcam, ab71495) and  $\alpha$ -tubulin (Santa Cruz, sc5286).

## Statistical analysis

Statistical analysis was determined by two-way ANOVA with Bonferroni post-test for weight curves. The Mann-Whitney test was utilized for all *in vivo* experiments, except where a one-column T-test with a hypothetical value of 1 was employed. *In vitro* experiments were analyzed by students T-test.  $p < 0.05$ . \* =  $p < 0.05$ , \*\* =  $p < 0.01$ , \*\*\* =  $p < 0.001$ .

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We thank Helen Ferry, Kate Alford and Nigel Rust for cell sorting, Richard Stillion for histology, staff at the University of Oxford for animal care, High Throughput Genomics, The Wellcome Trust Centre for Human Genetics for microarray services, Prof. Herman Waldmann and Prof. Richard Flavell for Foxp3<sup>hCD2</sup> and IL-10<sup>gfp</sup> mice respectively.


We are grateful for support from the Wellcome Trust (New Investigator Award to K.J. Maloy; Doctoral studentship to O.J. Harrison).

## Reference

1. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science*. 2012; 336:1268–1273. doi:10.1126/science.1223490. [PubMed: 22674334]
2. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature*. 2011; 474:298–306. doi:10.1038/nature10208. [PubMed: 21677746]
3. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. *Annual review of immunology*. 2009; 27:485–517. doi:10.1146/annurev.immunol.021908.132710.
4. Harrison OJ, Powrie FM. Regulatory T cells and immune tolerance in the intestine. *Cold Spring Harbor perspectives in biology*. 2013; 5 doi:10.1101/cshperspect.a018341.
5. Atarashi K, et al. ATP drives lamina propria T(H)17 cell differentiation. *Nature*. 2008; 455:808–812. doi:10.1038/nature07240. [PubMed: 18716618]
6. Ivanov II, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. *Cell host & microbe*. 2008; 4:337–349. doi:10.1016/j.chom.2008.09.009. [PubMed: 18854238]
7. Shaw MH, Kamada N, Kim YG, Nunez G. Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. *The Journal of experimental medicine*. 2012; 209:251–258. doi:10.1084/jem.20111703. [PubMed: 22291094]
8. Sims JE, Smith DE. The IL-1 family: regulators of immunity. *Nature reviews. Immunology*. 2010; 10:89–102. doi:10.1038/nri2691.
9. Okamura H, et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. *Infection and immunity*. 1995; 63:3966–3972. [PubMed: 7558306]

10. Robinson D, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. *Immunity*. 1997; 7:571–581. [PubMed: 9354477]
11. Smeltz RB, Chen J, Hu-Li J, Shevach EM. Regulation of interleukin (IL)-18 receptor alpha chain expression on CD4(+) T cells during T helper (Th)1/Th2 differentiation. Critical downregulatory role of IL-4. *The Journal of experimental medicine*. 2001; 194:143–153. [PubMed: 11457889]
12. Barrett JC, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nature genetics*. 2008; 40:955–962. doi:10.1038/ng.175. [PubMed: 18587394]
13. Hedl M, Zheng S, Abraham C. The IL18RAP Region Disease Polymorphism Decreases IL-18RAP/IL-18R1/IL-1R1 Expression and Signaling through Innate Receptor-Initiated Pathways. *Journal of immunology*. 2014 doi:10.4049/jimmunol.1302727.
14. Imielinski M, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. *Nature genetics*. 2009; 41:1335–1340. doi:10.1038/ng.489. [PubMed: 19915574]
15. Monteleone G, et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. *Journal of immunology*. 1999; 163:143–147.
16. Pizarro TT, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. *Journal of immunology*. 1999; 162:6829–6835.
17. Wirtz S, Becker C, Blumberg R, Galle PR, Neurath MF. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. *Journal of immunology*. 2002; 168:411–420.
18. Dupaul-Chicoine J, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. *Immunity*. 2010; 32:367–378. doi:10.1016/j.immuni.2010.02.012. [PubMed: 20226691]
19. Zaki MH, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. *Immunity*. 2010; 32:379–391. doi:10.1016/j.immuni.2010.03.003. [PubMed: 20303296]
20. Siegmund B. Interleukin-18 in intestinal inflammation: friend and foe? *Immunity*. 2010; 32:300–302. doi:10.1016/j.immuni.2010.03.010. [PubMed: 20346770]
21. Gutcher I, Urich E, Wolter K, Prinz M, Becher B. Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. *Nature immunology*. 2006; 7:946–953. doi:10.1038/ni1377. [PubMed: 16906165]
22. Schroder K, Tschopp J. The inflammasomes. *Cell*. 2010; 140:821–832. doi:10.1016/j.cell.2010.01.040. [PubMed: 20303873]
23. Pott J, et al. Age-dependent TLR3 expression of the intestinal epithelium contributes to rotavirus susceptibility. *PLoS pathogens*. 2012; 8:e1002670. doi:10.1371/journal.ppat.1002670. [PubMed: 22570612]
24. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity*. 2006; 24:179–189. doi:10.1016/j.immuni.2006.01.001. [PubMed: 16473830]
25. Adachi O, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. *Immunity*. 1998; 9:143–150. [PubMed: 9697844]
26. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. *Nature reviews. Immunology*. 2007; 7:353–364. doi:10.1038/nri2079.
27. Chung Y, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. *Immunity*. 2009; 30:576–587. doi:10.1016/j.immuni.2009.02.007. [PubMed: 19362022]
28. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. *International immunology*. 1993; 5:1461–1471. [PubMed: 7903159]
29. Izcue A, et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. *Immunity*. 2008; 28:559–570. doi:10.1016/j.immuni.2008.02.019. [PubMed: 18400195]
30. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science*. 2003; 299:1057–1061. doi:10.1126/science.1079490. [PubMed: 12522256]


31. Komatsu N, et al. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106:1903–1908. doi:10.1073/pnas.0811556106. [PubMed: 19174509]
32. Kamanaka M, et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. *Immunity*. 2006; 25:941–952. doi:10.1016/j.immuni.2006.09.013. [PubMed: 17137799]
33. Chaudhry A, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. *Science*. 2009; 326:986–991. doi:10.1126/science.1172702. [PubMed: 19797626]
34. Griseri T, Asquith M, Thompson C, Powrie F. OX40 is required for regulatory T cell-mediated control of colitis. *The Journal of experimental medicine*. 2010; 207:699–709. doi:10.1084/jem.20091618. [PubMed: 20368580]
35. Pesu M, et al. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. *Nature*. 2008; 455:246–250. doi:10.1038/nature07210. [PubMed: 18701887]
36. Vanvalkenburgh J, et al. Critical role of Bcl11b in suppressor function of T regulatory cells and prevention of inflammatory bowel disease. *The Journal of experimental medicine*. 2011; 208:2069–2081. doi:10.1084/jem.20102683. [PubMed: 21875956]
37. Coccia M, et al. IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. *The Journal of experimental medicine*. 2012; 209:1595–1609. doi:10.1084/jem.20111453. [PubMed: 22891275]
38. Schiering C, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. *Nature*. 2014; 513:564–568. doi:10.1038/nature13577. [PubMed: 25043027]
39. Elinav E, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. *Cell*. 2011; 145:745–757. doi:10.1016/j.cell.2011.04.022. [PubMed: 21565393]
40. Carpenter AC, et al. The transcription factors Thpok and LRF are necessary and partly redundant for T helper cell differentiation. *Immunity*. 2012; 37:622–633. doi:10.1016/j.immuni.2012.06.019. [PubMed: 23041065]
41. Ghoreschi K, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. *Nature*. 2010; 467:967–971. doi:10.1038/nature09447. [PubMed: 20962846]
42. Paulos CM, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. *The Journal of clinical investigation*. 2007; 117:2197–2204. doi:10.1172/JCI32205. [PubMed: 17657310]
43. Kanai T, et al. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. *Gastroenterology*. 2001; 121:875–888. [PubMed: 11606501]
44. Song-Zhao GX, Maloy KJ. Experimental mouse models of T cell-dependent inflammatory bowel disease. *Methods in molecular biology*. 2014; 1193:199–211. doi:10.1007/978-1-4939-1212-4\_18. [PubMed: 25151008]
45. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. *Bioinformatics*. 2008; 24:1547–1548. doi:10.1093/bioinformatics/btn224. [PubMed: 18467348]
46. Smyth, GK. *Bioinformatics and Computational Biology Solutions Using R and Bioconductor Statistics for Biology and Health*. Gentleman, Robert, et al., editors. Springer; New York: 2005. p. 397-420.Ch. 23



**Figure 1. IL-18R1<sup>+</sup> CD4<sup>+</sup> T cells are enriched within the colonic lamina propria**


(a) Naïve CD4<sup>+</sup> T cells were polarized to Th0, Th1, Th2, Th17 and iTreg lineages and gene expression assayed by qRT-PCR. (b) Representative FACS histograms of IL-18R1 expression by splenic and colonic CD62L<sup>+</sup> CD44<sup>-</sup> and CD44<sup>+</sup> CD62L<sup>-</sup> CD4<sup>+</sup> T cells from WT mice. (c) Representative FACS plots of IL-18R1 expression by colonic Th1, Th17 and Foxp3<sup>+</sup> Treg cells from WT mice. (d) Frequencies of IL-18R1<sup>+</sup> Th1, Th17 and Foxp3<sup>+</sup> Treg cells from the spleen, MLN and colon of WT mice. Data is shown as mean  $\pm$  S.E.M. and represents results from 2-3 independent experiments with consistent results. Each dot represents an individual mouse with n=4-5 mice/group.





### Figure 2. Canonical IL-18R1-signaling limits colonic Th17 cell differentiation


Colonic lamina propria leukocytes from steady state, co-housed WT, *Il18*<sup>-/-</sup> and *Il18r1*<sup>-/-</sup> mice were analyzed for CD4<sup>+</sup> T cell subset frequencies. (a) Representative FACS plots of IL-17A and IFN-γ production by CD4<sup>+</sup> T cells. Frequencies of (b) colonic Th1 and Th17 cells and (c) colonic Foxp3<sup>+</sup> Treg cells from indicated mice. (d) Cytokine production from α-CD3 stimulated colonic lamina propria leukocytes from WT and *Il18r1*<sup>-/-</sup> mice. (e) Antimicrobial peptide gene expression from colonic tissue of WT and *Il18r1*<sup>-/-</sup> mice. Data is shown as mean ± S.E.M. and represents results from 2-3 independent experiments with consistent results. Each dot represents an individual mouse with n=4-5 mice/group.



### Figure 3. IEC-derived IL-18 regulates colonic Th17 cell differentiation


(a) Representative confocal microscopy images of colonic tissue from WT and *Il18<sup>-/-</sup>* mice; IL-18 (red), E-cadherin (green) and DAPI (blue). Scale bar = 50 $\mu$ m. (b) Protein extracts from enriched IEC or cLPL analyzed by Western blot with  $\alpha$ -IL-18 and  $\alpha$ -tubulin (loading control). Lethally irradiated WT and *Il18<sup>-/-</sup>* mice received WT or *Il18<sup>-/-</sup>* bone marrow cells to generate chimeric mice. (c) Representative FACS plots of IL-17A and IFN- $\gamma$  production by colonic CD4<sup>+</sup> T cells from chimeric mice. (d) Frequencies of colonic Th1, Th17 and Foxp3<sup>+</sup> Treg cells from chimeric mice.

Data represents results from 2-3 independent experiments. Each dot represents an individual mouse with n=4-5 mice/group.




**Figure 4. Cell-intrinsic IL-18R1-signaling inhibits colonic Th17 cell differentiation**  
 Lethally irradiated *Rag1*<sup>-/-</sup> mice received a 1:1 mixture of CD45.1 WT and CD45.2 *Il18r1*<sup>-/-</sup> bone marrow cells. (a) Representative FACS plots of IL-17A and IFN- $\gamma$  production by colonic CD4<sup>+</sup> T cells from chimeric mice. (b) Frequencies of colonic Th1, Th17 and Foxp3<sup>+</sup> Treg cells from chimeric mice. (c) Relative contribution of WT and *Il18r1*<sup>-/-</sup> CD4<sup>+</sup> T cells to Th1, Th17 and Foxp3<sup>+</sup> Treg cell pools in chimeric mice. Equal contribution = 1, against which statistical significance was calculated using a 1 column T-test. Ratio > 1 indicates elevated contribution from *Il18r1*<sup>-/-</sup> progeny, ratio < 1 indicates diminished contribution from *Il18r1*<sup>-/-</sup> progeny. (d) Representative FACS plots of IL-17A and IFN- $\gamma$

production and (e) frequencies of Th17 cell differentiation by polarized WT or *Il18r1*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells in the presence or absence of IL-18. (f) Representative FACS plots of IL-17A and IFN- $\gamma$  production and (g) frequencies of Th17 cell differentiation by polarized WT, *Il1r1*<sup>-/-</sup> and *Myd88*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells in the presence or absence of IL-18. Data shown as mean  $\pm$  S.E.M. and represents results pooled from 2-3 independent experiments. Each dot represents an individual chimeric mouse with n=5-6 mice/group.



**Figure 5. IL-18R1-signaling is dispensable for induction of CD4<sup>+</sup> T cell mediated colitis**  
*Rag1*<sup>-/-</sup> mice received WT or *Il18r1*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells. (a) Representative confocal microscopy images of colonic tissue from *Rag1*<sup>-/-</sup> mice receiving WT naïve CD4<sup>+</sup> T cells. IL-18 (red), E-cadherin (green) and DAPI (blue). Scale bar = 50µm. (b) Representative weight loss curves and (c) colonic inflammation scores of *Rag1*<sup>-/-</sup> mice alone, or receiving WT or *Il18r1*<sup>-/-</sup> naïve CD4<sup>+</sup> T cells. Data shown as mean is representative of 2 independent experiments. Each dot represents an individual chimeric mouse with n=4-5 mice/group.



**Figure 6. Canonical IL-18R1-signaling is critical for Foxp3<sup>+</sup> Treg cell mediated control of colitis** *Rag1*<sup>-/-</sup> mice received CD45.1<sup>+</sup> naïve CD4<sup>+</sup> T cells alone, or in combination with CD45.2<sup>+</sup> WT or *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells. (a) Representative FACS analysis and (b) percentages of colonic Foxp3<sup>+</sup> Treg cell expression of IL-18R1 from *Rag1*<sup>-/-</sup> mice receiving WT naïve CD4<sup>+</sup> T cells and Foxp3<sup>+</sup> Treg cells. (c) Representative weight loss curves, (d) histological sections and (e) colonic inflammation scores of *Rag1*<sup>-/-</sup> mice receiving CD45.1<sup>+</sup> naïve CD4<sup>+</sup> T cells alone, in combination with WT or *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells, or *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells alone. (f) Frequencies of colonic CD45.2<sup>+</sup> T cells, expressing Foxp3, and producing IL-10, from *Rag1*<sup>-/-</sup> mice receiving CD45.1<sup>+</sup> naïve CD4<sup>+</sup> T cells in combination with WT or *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells. (g) qRT-PCR validation of differential gene expression by WT and *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells from *Rag1*<sup>-/-</sup> mice receiving CD45.1<sup>+</sup> naïve CD4<sup>+</sup> and CD25<sup>+</sup> Treg cells in combination with CD45.2<sup>+</sup> WT or *Il18r1*<sup>-/-</sup> Foxp3<sup>+</sup> Treg cells. Data is shown as mean ± S.E.M. and represents results from 2-3 independent experiments. Each dot represents an individual mouse with n=2-6 mice/group.